Dupilumab Effect on Exacerbations and Lung Function Despite Withdrawal of Inhaled Corticosteroids/long-Acting Beta Agonists
No Thumbnail Available
Authors
Wechsler M.E.
Pfeffer P.
Jackson D.J.
Rabe K.F.
Pavord I.D.
Virchow J.C.
Katial R.
Israel E.
Xia C.
PanditAbid N.
Contact
Check for full-text access
Issue Date
2024
Type
Conference Proceedings
Language
Keywords
Alternative Title
Abstract
Background Dupilumab reduces severe exacerbations, improves lung function in patients with moderate-to-severe asthma, and demonstrates an acceptable safety profile. Reduction of inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) dose is recommended in patients who respond to biologics, but little evidence is available regarding the safety of such reduction. This analysis evaluated the impact of ICS/LABA withdrawal on exacerbations and lung function in patients with asthma and baseline eosinophils >=300 cells/muL in 2 clinical studies (Phase 2a NCT01312961] and Phase 2 NCT03387852]). Method Patients (>=18 years) received dupilumab 300 mg weekly (Phase 2a) or dupilumab 300 mg every 2 weeks (Phase 2) for 12 weeks or placebo. LABA was discontinued at Week 4, and ICS tapered over Weeks 6 to 9. Adjusted annualized exacerbation rates, changes from baseline to Week 12 and from Week 4 to 12 in pre-bronchodilator (BD) forced expiratory volume in 1 second (FEV1), and proportions of patients who maintained 5-item Asthma Control Questionnaire (ACQ- 5) scores ), and proportions of patients who maintained 5-item Asthma Control Questionnaire (ACQ- 5) scores 1 significantly improved from baseline to Week 12 in both studies. No further improvements in pre-BD FEV1 were observed from Week 4 (after LABA discontinuation) to Week 12 (table 1). By Week 12, 62.0/61.3% (dupilumab) and 38.3/36.6% (placebo) of patients in Phase2a/Phase 2 studies were able to withdraw ICS while maintaining asthma control (ACQ-5 <1.5). Conclusion Dupilumab reduced exacerbations and significantly improved lung function despite ICS/LABA withdrawal in patients with moderate-to-severe asthma. (Table Presented).
Description
Citation
Publisher
License
Journal
Thorax